SANDOZ FENTANYL PATCH 100 MCG
FENTANYL : 100 MCG · DIN 02327163 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is SANDOZ FENTANYL PATCH?
SANDOZ FENTANYL PATCH 100 MCG contains FENTANYL : 100 MCG. It is listed in the Health Canada Drug Product Database under DIN 02327163, held by SANDOZ CANADA INCORPORATED, supplied as PATCH for TRANSDERMAL administration. Health Canada currently lists it as marketed, status dated 01-Nov-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SANDOZ FENTANYL PATCH used for?
Management of pain severe enough to require daily, continuous, long-term opioid treatment that is opioid-responsive and for which alternative options are inadequate.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02327163 |
|---|---|
| Brand name | SANDOZ FENTANYL PATCH |
| Generic / active ingredient | FENTANYL : 100 MCG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 100 MCG |
| Dosage form | PATCH |
| Route of administration | TRANSDERMAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AB03 FENTANYL |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Nov-2010 |
| Original market date | 2010-11-01 00:00:00 |
How is it administered?
For opioid-tolerant patients only (≥60mg/day morphine equivalents). Apply to intact skin; replace every 72 hours. Initial dose based on conversion from prior opioids. Do not abruptly discontinue.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents points to page 32, but text ends earlier).
How is it supplied?
Not explicitly detailed in provided text (mentions strengths 12, 25, 37, 50, 75, 100 mcg/h).
Contraindications
Acute/perioperative pain; mild/intermittent pain; opioid-naive patients; severe respiratory depression; severe asthma; GI obstruction; hypersensitivity to fentanyl; pregnancy/breast-feeding.
Warnings and precautions
Risk of addiction, abuse, misuse; life-threatening respiratory depression; fatal overdose if used by non-opioid tolerant; avoid external heat sources; accidental exposure can be fatal.
Is FENTANYL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02AB03 FENTANYL. 16 of 84 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| FENTORA | 100 MCG | TABLET (EFFERVESCENT) | TEVA CANADA LIMITED | MARKETED | DIN 02408007 |
| FENTORA | 200 MCG | TABLET (EFFERVESCENT) | TEVA CANADA LIMITED | MARKETED | DIN 02408015 |
| FENTORA | 400 MCG | TABLET (EFFERVESCENT) | TEVA CANADA LIMITED | MARKETED | DIN 02408023 |
| FENTORA | 600 MCG | TABLET (EFFERVESCENT) | TEVA CANADA LIMITED | MARKETED | DIN 02408031 |
| FENTORA | 800 MCG | TABLET (EFFERVESCENT) | TEVA CANADA LIMITED | MARKETED | DIN 02408058 |
| SANDOZ FENTANYL PATCH | 12 MCG | PATCH | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02327112 |
| SANDOZ FENTANYL PATCH | 25 MCG | PATCH | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02327120 |
| SANDOZ FENTANYL PATCH | 37 MCG | PATCH | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02327139 |
| SANDOZ FENTANYL PATCH | 50 MCG | PATCH | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02327147 |
| SANDOZ FENTANYL PATCH | 75 MCG | PATCH | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02327155 |
Who else supplies FENTANYL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FENTANYL appears in 541 registered pack listings across 13 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.